3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
105
Skin Neoplasms
17
Neoplasm Metastasis
15
Neoplasms
10
Uveal Melanoma
9
Carcinoma, Renal Cell
9
Carcinoma, Non-Small-Cell Lung
9
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Lymphoma
2
Eye Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Turcot syndrome
1
Sezary Syndrome
1
Sarcoma, Synovial
1
Interventions
atezolizumab
2
vedolizumab
1
Taste
1
Radiotherapy
1
National Cancer Institute (U.S.)
1
Loperamide
1
LDP-02
1
Interleukin-2
1
Infliximab
1
Immunotherapy
1
Immunoglobulin G
1
Fecal Microbiota Transplantation
1
Fatty Acids, Omega-3
1
Drug Therapy
1
Disulfides
1
CT-P13
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled